This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.80% per year. These returns cover a period from January 1, 1988 through August 3, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Zacks.com featured highlights include Insulet, Sandisk and O-I Glass
by Zacks Equity Research
Insulet, Sandisk and O-I Glass have been highlighted in this Screen of The Week article.
3 Stocks With Upgraded Broker Ratings to Buy for Solid Returns
by Swayta Shah
Upgraded broker ratings bring the spotlight to PODD, SNDK and OI as potential picks in a selective market, each showing strong earnings growth and momentum.
Why Insulet (PODD) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Medtronic's Q2 Earnings & Revenues Beat Estimates, Stock Climbs
by Zacks Equity Research
MDT posts Q2 earnings and revenue beat, powered by strong Cardiovascular growth and a raised 2026 outlook that lifts its shares.
Zacks Industry Outlook Highlights Boston Scientific, Insulet, BioLife Solutions and Allurion
by Zacks Equity Research
Boston Scientific, Insulet, BioLife Solutions and Allurion push ahead with innovation and efficiency as the Medical Products industry faces pressure.
Do Options Traders Know Something About Insulet Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to PODD stock based on the movements in the options market lately.
4 Medical Product Stocks to Watch From a Challenging Industry
by Indrajit Bandyopadhyay
The Zacks Medical products industry sees steady demand, but macro headwinds keep growth under pressure in 2025. BSX, PODD, BLFS and ALUR reflect the favorable fundamentals.
Why Insulet (PODD) Might be Well Poised for a Surge
by Zacks Equity Research
Insulet (PODD) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Best Momentum Stocks to Buy for Nov. 13
by Zacks Equity Research
FLEX, PODD and PRAA made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on Nov. 13, 2025.
Insulet Stock Up Post Q3 Earnings & Revenue Beat, Margins Expand
by Zacks Equity Research
PODD's Q3 earnings and revenues top forecasts, with strong Omnipod growth and margin expansion lifting shares.